Clinical Scorecard: Forecasting Hospital Admissions for Genitourinary Issues Post-Radiation in Patients with Localized Prostate Cancer

At a Glance

Key Highlights

• Diabetes, smoking, and bladder outlet obstruction without prior TURP are strong independent predictors of hospital admission for treatment-related genitourinary toxicity.
• Patients with BOO without TURP have the lowest 10-year event-free survival rates for genitourinary toxicity requiring hospital admission.
• A novel predictive model incorporating clinical factors was developed and internally validated to forecast genitourinary toxicity-related hospital admissions post-EBRT.

Guideline-Based Recommendations

Diagnosis

• Assess baseline urinary symptoms and comorbidities including diabetes and smoking history prior to EBRT.
• Identify presence of bladder outlet obstruction and history of TURP before radiotherapy.
• Use linked clinical and hospital admission data to monitor genitourinary toxicity events such as haematuria, cystitis, urethral stricture, urinary incontinence, and retention.

Management

• Consider risk stratification for genitourinary toxicity based on clinical factors to guide patient counseling and treatment planning.
• Monitor and manage comorbidities like diabetes and smoking cessation to potentially reduce toxicity risk.
• Evaluate the need for TURP in patients with BOO prior to EBRT to potentially mitigate severe genitourinary toxicity.

Monitoring & Follow-up

• Use hospital admission data and clinical follow-up to track genitourinary toxicity events post-EBRT.
• Apply predictive models and decision curve analysis to identify high-risk patients for closer surveillance.
• Regularly assess urinary function and symptoms during and after radiotherapy.

Risks

• Increased risk of hospital admission for genitourinary toxicity in patients with diabetes, smoking history, and BOO without TURP.
• Baseline stress urinary incontinence is associated with toxicity but may be confounded by other factors.
• Higher radiation doses (>80 Gy) and treatment era (pre-2009 vs post-2009) may influence toxicity profiles.

Patient & Prescribing Data

Men with localized prostate cancer treated with curative intent EBRT in South Australia from 1998 to 2019

Clinical factors such as diabetes, smoking, and BOO status should be considered alongside dosimetric parameters to predict and manage genitourinary toxicity risk.

Clinical Best Practices

• Incorporate comprehensive baseline clinical assessment including comorbidities and urinary function before EBRT.
• Use validated predictive models to inform patient counseling and individualized treatment planning.
• Consider multidisciplinary input (urology, radiation oncology, epidemiology) in toxicity risk assessment and management.
• Apply adaptive radiotherapy techniques and dose constraints informed by patient risk profiles to minimize toxicity.
• Implement ongoing monitoring and early intervention strategies for patients at high risk of genitourinary toxicity.

References

• South Australian Prostate Cancer Clinical Outcome Collaborative (SA-PCCOC) registry
• TRIPOD statement for predictive model development
• Steyerberg et al. ABCD approach for model validation
• Decision curve analysis methodology